AlphaFold and AlphaProteo: From Proteins to Patients

AlphaFold 3's "Pairformer" -- an artificial intelligence (AI) program developed by Google that performs predictions of protein structure -- The program is designed as a deep learning system can now predict complex molecular interactions in minutes instead of months, leading to breakthroughs like the 30-day development of a promising liver cancer treatment. The mind-blowing 88% success rate of AlphaProteo in designing proteins that work in the lab is revolutionizing what we thought was possible in drug development. 

Add the growing infusion of AI within Manufacturing Execution Systems, and we’re starting to see personalized medicine become a reality with molecular tailoring instead of one-size-fits-all treatments. By 2025 we'll see the first AI-designed drugs getting FDA approval, potentially reducing drug development costs and time by up to 70%. 

Check out our latest Industry Insights episode and hear more about the brilliance of AlphaFold, why it's such a big deal, and how it's being paired with advanced manufacturing systems to create treatments that could save millions of lives. 

Join us as we cover the future of medicine in which no disease is untreatable, treatments are perfectly tailored to each person, and human ingenuity work together to keep us healthy.